These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 15705084

  • 1. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
    Steers W, Corcos J, Foote J, Kralidis G.
    BJU Int; 2005 Mar; 95(4):580-6. PubMed ID: 15705084
    [Abstract] [Full Text] [Related]

  • 2. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
    Haab F, Stewart L, Dwyer P.
    Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
    Haab F, Corcos J, Siami P, Glavind K, Dwyer P, Steel M, Kawakami F, Lheritier K, Steers WD.
    BJU Int; 2006 Nov; 98(5):1025-32. PubMed ID: 16879437
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.
    Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, Haab F.
    Int J Clin Pract; 2006 Jan; 60(1):119-26. PubMed ID: 16409440
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Increased warning time with darifenacin: a new concept in the management of urinary urgency.
    Cardozo L, Dixon A.
    J Urol; 2005 Apr; 173(4):1214-8. PubMed ID: 15758755
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
    Haab F, Cardozo L, Chapple C, Ridder AM, Solifenacin Study Group.
    Eur Urol; 2005 Mar; 47(3):376-84. PubMed ID: 15716204
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
    Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, Wang J, Brodsky M, Bavendam T.
    J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
    Hill S, Khullar V, Wyndaele JJ, Lheritier K, Darifenacin Study Group.
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 May; 17(3):239-47. PubMed ID: 15999217
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
    Kay GG, Wesnes KA.
    BJU Int; 2005 Nov; 96(7):1055-62. PubMed ID: 16225528
    [Abstract] [Full Text] [Related]

  • 19. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M, Japanese Solifenacin Study Group.
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.